EUVIMEDObjevte EUVIMED
Crossref

Farnesol Targets the GSTP1 / MAPK Axis to Inhibit Trauma‐Induced Tendon Heterotopic Ossification

Xiao Deng, Tong Li iD, Guanzhi Li iD, Tingrun Zhu, Yuyun Kong, Baizheng Fu, Jiao Jiao Li, Chao Chen, Wenxiong Lei, Guiyong Jiang, Kairui Zhang

Phytotherapy Research · 2026

DOI: 10.1002/ptr.70283 ↗

At a glance

Journal article in Phytotherapy Research, 2026. Written by Xiao Deng and 10 co-authors. Institution: Division of Orthopaedics and Traumatology, Department of Orthopaedics, Nanfang Hospital, Southern Medical University, Guangzhou, China. Major MEDLINE topics: Ossification, Heterotopic, Farnesol, Glutathione S-Transferase pi, Tendon Injuries. 57 references. Funded by: Basic and Applied Basic Research Foundation of Guangdong Province, National Natural Science Foundation of China, Administration of Traditional Chinese Medicine of Guangdong Province, China.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Heterotopic ossification (HO) within tendons leads to debilitating tissue dysfunction, primarily arising from the abnormal osteogenic differentiation of tendon‐derived stem cells (TDSCs). Despite its clinical prevalence, effective pharmacological treatments remain elusive. Farnesol, a natural isoprenoid with potent anti‐inflammatory properties, represents a novel but unexplored candidate for musculoskeletal repair. This study aimed to evaluate the therapeutic efficacy of Farnesol in attenuating tendon HO and to elucidate the specific molecular mechanisms driving its effects. The anti‐osteogenic effects of Farnesol were assessed using in vitro TDSC differentiation assays and an in vivo tendon injury model. Integrated RNA sequencing and network pharmacology analysis were employed to identify potential molecular targets. The mechanism was rigorously validated through rescue experiments using a specific GSTP1 inhibitor. Farnesol treatment significantly inhibited osteogenic differentiation in vitro and attenuated ectopic bone formation in vivo. Mechanistic screening identified the GSTP1/MAPK signaling axis as a critical regulatory pathway. Crucially, the administration of a GSTP1 inhibitor reversed the suppressive effects of Farnesol on osteogenesis, confirming GSTP1 as the primary mediator. Farnesol effectively inhibits the progression of post‐traumatic tendon HO by targeting the GSTP1/MAPK pathway. These findings provide the first evidence of Farnesol's therapeutic potential in preventing pathological ossification.

Subjects

MeSH terms (MEDLINE)

Ossification, HeterotopicFarnesolGlutathione S-Transferase piTendon InjuriesMAP Kinase Signaling SystemAnimalsOsteogenesisCell DifferentiationTendonsStem CellsMiceMale

Author keywords

FarnesolGSTP1/MAPK axisheterotopic ossificationtendon injurytendon‐derived stem cells

Substances

FarnesolGlutathione S-Transferase pi

Authors and institutions

  • Division of Orthopaedics and Traumatology, Department of Orthopaedics, Nanfang Hospital, Southern Medical University, Guangzhou, China.
  • School of Biomedical Sciences and Engineering, South China University of Technology, Guangzhou, China.
  • Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, People's Republic of China.
  • School of Biomedical Engineering, Faculty of Engineering and IT, University of Technology Sydney, Sydney, New South Wales, Australia.
  • Department of Orthopaedics, School of Traditional Chinese Medicine, Southern Medical University, Guangzhou, China.
  • Department of Emergency Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, China.

ORCID profiles: Tong Li, Guanzhi Li

Funding

  • Basic and Applied Basic Research Foundation of Guangdong Province
  • National Natural Science Foundation of China
  • Administration of Traditional Chinese Medicine of Guangdong Province, China
  • Rebecca L. Cooper Medical Research Foundation

Cite

APA

Deng, X., Li, T., Li, G., Zhu, T., Kong, Y., Fu, B., Li, J. J., Chen, C., Lei, W., Jiang, G., & Zhang, K. (2026). Farnesol Targets the GSTP1 / MAPK Axis to Inhibit Trauma‐Induced Tendon Heterotopic Ossification. Phytotherapy Research. https://doi.org/10.1002/ptr.70283

Vancouver

Deng X, Li T, Li G, Zhu T, Kong Y, Fu B, et al. Farnesol Targets the GSTP1 / MAPK Axis to Inhibit Trauma‐Induced Tendon Heterotopic Ossification. Phytotherapy Research. 2026. doi:10.1002/ptr.70283

BibTeX
@article{Deng2026,
  author = {Deng, Xiao and Li, Tong and Li, Guanzhi and Zhu, Tingrun and Kong, Yuyun and Fu, Baizheng and Li, Jiao Jiao and Chen, Chao and Lei, Wenxiong and Jiang, Guiyong and Zhang, Kairui},
  title = {Farnesol Targets the GSTP1 / MAPK Axis to Inhibit Trauma‐Induced Tendon Heterotopic Ossification},
  journal = {Phytotherapy Research},
  year = {2026},
  doi = {10.1002/ptr.70283}
}
Start for free →